Production (Stage)
Edgewise Therapeutics, Inc.
EWTX
$15.29
-$0.13-0.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 34.01M | 31.87M | 28.87M | 26.33M | 24.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 170.04M | 158.83M | 147.15M | 136.17M | 123.41M |
| Operating Income | -170.04M | -158.83M | -147.15M | -136.17M | -123.41M |
| Income Before Tax | -146.09M | -133.81M | -124.29M | -115.88M | -105.85M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -146.09 | -133.81 | -124.29 | -115.88 | -105.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -146.09M | -133.81M | -124.29M | -115.88M | -105.85M |
| EBIT | -170.04M | -158.83M | -147.15M | -136.17M | -123.41M |
| EBITDA | -167.93M | -156.76M | -145.18M | -134.29M | -121.58M |
| EPS Basic | -1.55 | -1.45 | -1.49 | -1.53 | -1.54 |
| Normalized Basic EPS | -0.97 | -0.90 | -0.93 | -0.96 | -0.96 |
| EPS Diluted | -1.55 | -1.45 | -1.49 | -1.53 | -1.54 |
| Normalized Diluted EPS | -0.97 | -0.90 | -0.93 | -0.96 | -0.96 |
| Average Basic Shares Outstanding | 377.18M | 369.62M | 339.67M | 309.32M | 279.18M |
| Average Diluted Shares Outstanding | 377.18M | 369.62M | 339.67M | 309.32M | 279.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |